Orchard Therapeutics Limited
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Orchard Therapeutics Limited
Only two breakthrough-designated novel agents remain on the US FDA drugs center’s 2023 user fee calendar, while CBER stacks up on vaccines and gene therapies under both BTD and RMAT programs.
Institute for Clinical and Economic Review continues to assign high values to novel gene therapies, suggesting that Orchard’s pending ‘arsa-cel’ for MLD could be cost effective at a price as high as $4 million per treatment.
Highlights of recent submissions for approval from the Pink Sheet’s US FDA Performance Tracker
The Japan-based drug maker is hoping to expand into cell and gene therapy as well as enlarge its presence in the North American market, while Orchard awaits an FDA verdict on Libmeldy.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Orchard Therapeutics (Europe) Limited, Orchard Therapeutics North America
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.